Sanofi: No pancreatitis problems for Lyxumia

According to Sanofi’s global diabetes chief, recent debate over concerns about an increased risk of pancreatic inflammation linked to the diabetes drug type GLP-1 will have an impact on the FDA’s view on the drug class.

Foto: Sanofi/PR

There have been a few indications about an increased risk of acute inflammation of the pancreas arising from the use of Sanofis diabetes drug Lyxumia, but the company is keeping a watchful eye out, Riccardo Perfetti, Vice President Medical Affairs, Global Division, in Sanofi tells Medwatch following recent studies and heavy debate about the class of diabetes drugs known as GLP-1s – a class that Lyxumia belongs to as well.

“You should bear in mind that as soon as there is one report about a potential increased risk of pancreatitis from the drug, it will naturally lead to even more reports. It is difficult to assess if the increased number of reports is due to more doctors and patients being told to look out for this side effect,” the VP says, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier